DekaBank Deutsche Girozentrale’s XORTX Therapeutics XRTX Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio XRTX Stock Details XRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-552,418	Closed	-$161M	–	1520
2023 Q4	$161M	Buy	+552,418	New	+$40.8M	0.33%	71

Other funds holding XRTX

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return

DekaBank Deutsche Girozentrale's XRTX Position: Q1 2024 in Review

DekaBank Deutsche Girozentrale sold out of XORTX Therapeutics (XRTX) in Q1 2024, closing a stake of 552,418 shares — an estimated $161M sold.

DekaBank Deutsche Girozentrale first reported a position in XRTX in Q4 2023 and held it in 1 quarter. The position peaked at $161M in Q4 2023. 4 funds tracked by Wall St. Rank hold XRTX as of Q1 2024.

DekaBank Deutsche Girozentrale reported no remaining XORTX Therapeutics position as of Q1 2024 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 552,418 XORTX Therapeutics shares in Q1 2024, an estimated $161M.
DekaBank Deutsche Girozentrale first reported a position in XORTX Therapeutics in Q4 2023 and held it in 1 quarter.
DekaBank Deutsche Girozentrale's XORTX Therapeutics position peaked at $161M in Q4 2023.
4 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q1 2024.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2024, filed 24 Apr 2024.